{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:50Z","timestamp":1794048830081,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.rmed.2021.106307","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T22:46:06Z","timestamp":1610405166000},"page":"106307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pneumococal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance"],"prefix":"10.1016","volume":"177","author":[{"given":"Andrew F.","family":"Shorr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Micek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin H.","family":"Kollef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2021.106307_bib1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccm.2018.07.006","article-title":"Guidelines to manage community-acquired pneumonia","volume":"39","author":"Wunderink","year":"2018","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.rmed.2021.106307_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1055\/s-0036-1592313","article-title":"Community-acquired pneumonia: a global perspective","volume":"37","author":"Waterer","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2021.106307_bib3","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2021.106307_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.rmed.2021.106307_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community- acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106307_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","article-title":"Fluoroquinolones or macrolides alone versus combined with \u03b2-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis","volume":"46","author":"Raz-Pasteur","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.rmed.2021.106307_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.rmed.2018.05.020","article-title":"Macrolide therapy is associated with lower mortality in community- acquired bacteraemic pneumonia","volume":"140","author":"Arnold","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2021.106307_bib8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous {beta}-lactam\/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2021.106307_bib9","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2021.106307_bib10","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.rmed.2007.04.018","article-title":"Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re- admission","volume":"101","author":"Reyes Calzada","year":"2007","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2021.106307_bib11","doi-asserted-by":"crossref","first-page":"j2471","DOI":"10.1136\/bmj.j2471","article-title":"Advances in the causes and management of community acquired pneumonia in adults","volume":"358","author":"Wunderink","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.rmed.2021.106307_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2334-14-61","article-title":"Clinical implications for patients treated inappropriately for community-acquired pneumonia in the emergency department","volume":"14","author":"Micek","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.rmed.2021.106307_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fcimb.2016.00098","article-title":"Macrolide resistance in Streptococcus pneumoniae","volume":"6","author":"Schroeder","year":"2016","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.rmed.2021.106307_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chron. Dis."},{"key":"10.1016\/j.rmed.2021.106307_bib15","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"Apache II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.rmed.2021.106307_bib16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.rmed.2021.106307_bib17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jiac.2019.05.027","article-title":"Azithromycin plus \u03b2-lactam versus levofloxacin plus \u03b2-lactam for severe community-acquired pneumonia: a retrospective nationwide database analysis","volume":"25","author":"Suzuki","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.rmed.2021.106307_bib18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1164\/rccm.201502-0212OC","article-title":"The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia","volume":"191","author":"Cilloniz","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2021.106307_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/46.1.19","article-title":"Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae","volume":"46","author":"Koch","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.rmed.2021.106307_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-015-9822-7","article-title":"Macrolide use and neutrophil function\/cytokine levels in hospitalized patients with community-acquired pneumonia: a pilot study","volume":"194","author":"Arnold","year":"2016","journal-title":"Lung"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611121000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:11:57Z","timestamp":1760616717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611121000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":20,"alternative-id":["S0954611121000135"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106307","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumococal community-acquired pneumonia in the intensive care unit: Azithromycin remains protective despite macrolide resistance","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2021.106307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106307"}}